Potential biofluid markers and treatment targets for renal cell carcinoma

Hiromi I. Wettersten, Robert H Weiss

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Renal cell carcinoma (RCC) is the 13th most common cancer in the world and one of the few cancers for which incidence is increasing. This disease is generally asymptomatic at an early stage and is highly metastatic. Frequently discovered by physicians in the process of working up other diseases such as acute kidney injury, RCC is often discovered in an advanced form and many patients have metastases at the time of diagnosis. Given that life expectancy with currently approved therapies for metastatic RCC is approximately 1-2 years, biomarkers for RCC that will enable early detection are urgently needed. Although it is unlikely that highly sensitive and specific biomarkers will be identified in the near future that are useful for screening the general population, a noninvasive marker or set of markers could soon be used in general medicine, nephrology, and urology clinics to screen patients at increased risk of RCC. In addition to the ongoing need for RCC biomarkers, the frequent resistance reported with currently available targeted therapies makes the identification of new therapeutic targets similarly important. Many promising leads for new targeted therapies have come to light; some of these therapies are in clinical trials and others are still being evaluated in the laboratory.

Original languageEnglish (US)
Pages (from-to)336-344
Number of pages9
JournalNature Reviews Urology
Volume10
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Renal Cell Carcinoma
Biomarkers
Therapeutics
Nephrology
Urology
Life Expectancy
Acute Kidney Injury
Neoplasms
Medicine
Clinical Trials
Neoplasm Metastasis
Physicians
Incidence
Population

ASJC Scopus subject areas

  • Urology

Cite this

Potential biofluid markers and treatment targets for renal cell carcinoma. / Wettersten, Hiromi I.; Weiss, Robert H.

In: Nature Reviews Urology, Vol. 10, No. 6, 06.2013, p. 336-344.

Research output: Contribution to journalArticle

@article{8731de53f91747088371ac51bc003eb5,
title = "Potential biofluid markers and treatment targets for renal cell carcinoma",
abstract = "Renal cell carcinoma (RCC) is the 13th most common cancer in the world and one of the few cancers for which incidence is increasing. This disease is generally asymptomatic at an early stage and is highly metastatic. Frequently discovered by physicians in the process of working up other diseases such as acute kidney injury, RCC is often discovered in an advanced form and many patients have metastases at the time of diagnosis. Given that life expectancy with currently approved therapies for metastatic RCC is approximately 1-2 years, biomarkers for RCC that will enable early detection are urgently needed. Although it is unlikely that highly sensitive and specific biomarkers will be identified in the near future that are useful for screening the general population, a noninvasive marker or set of markers could soon be used in general medicine, nephrology, and urology clinics to screen patients at increased risk of RCC. In addition to the ongoing need for RCC biomarkers, the frequent resistance reported with currently available targeted therapies makes the identification of new therapeutic targets similarly important. Many promising leads for new targeted therapies have come to light; some of these therapies are in clinical trials and others are still being evaluated in the laboratory.",
author = "Wettersten, {Hiromi I.} and Weiss, {Robert H}",
year = "2013",
month = "6",
doi = "10.1038/nrurol.2013.52",
language = "English (US)",
volume = "10",
pages = "336--344",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Potential biofluid markers and treatment targets for renal cell carcinoma

AU - Wettersten, Hiromi I.

AU - Weiss, Robert H

PY - 2013/6

Y1 - 2013/6

N2 - Renal cell carcinoma (RCC) is the 13th most common cancer in the world and one of the few cancers for which incidence is increasing. This disease is generally asymptomatic at an early stage and is highly metastatic. Frequently discovered by physicians in the process of working up other diseases such as acute kidney injury, RCC is often discovered in an advanced form and many patients have metastases at the time of diagnosis. Given that life expectancy with currently approved therapies for metastatic RCC is approximately 1-2 years, biomarkers for RCC that will enable early detection are urgently needed. Although it is unlikely that highly sensitive and specific biomarkers will be identified in the near future that are useful for screening the general population, a noninvasive marker or set of markers could soon be used in general medicine, nephrology, and urology clinics to screen patients at increased risk of RCC. In addition to the ongoing need for RCC biomarkers, the frequent resistance reported with currently available targeted therapies makes the identification of new therapeutic targets similarly important. Many promising leads for new targeted therapies have come to light; some of these therapies are in clinical trials and others are still being evaluated in the laboratory.

AB - Renal cell carcinoma (RCC) is the 13th most common cancer in the world and one of the few cancers for which incidence is increasing. This disease is generally asymptomatic at an early stage and is highly metastatic. Frequently discovered by physicians in the process of working up other diseases such as acute kidney injury, RCC is often discovered in an advanced form and many patients have metastases at the time of diagnosis. Given that life expectancy with currently approved therapies for metastatic RCC is approximately 1-2 years, biomarkers for RCC that will enable early detection are urgently needed. Although it is unlikely that highly sensitive and specific biomarkers will be identified in the near future that are useful for screening the general population, a noninvasive marker or set of markers could soon be used in general medicine, nephrology, and urology clinics to screen patients at increased risk of RCC. In addition to the ongoing need for RCC biomarkers, the frequent resistance reported with currently available targeted therapies makes the identification of new therapeutic targets similarly important. Many promising leads for new targeted therapies have come to light; some of these therapies are in clinical trials and others are still being evaluated in the laboratory.

UR - http://www.scopus.com/inward/record.url?scp=84880273186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880273186&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2013.52

DO - 10.1038/nrurol.2013.52

M3 - Article

C2 - 23545813

AN - SCOPUS:84880273186

VL - 10

SP - 336

EP - 344

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 6

ER -